Geron Corporation (GERN)
NASDAQ • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Geron Corporation keeps $2 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Geron’s revenue rose 27% year over year to about $60.2 million in the third fiscal quarter of 2026, reported November 4, 2026, coming in line with consensus at $60.2 million versus a $60.4 million estimate (-0.3%). The top line increased from roughly $47.2 million a year ago as the company continued to be driven by its imetelstat-focused business. Geron generated operating cash flow of about $10.3 million during the quarter. Looking ahead, next-period consensus calls for EPS of -$0.01 on revenue of $66.0 million.
About Geron Corporation
Geron Corporation is a NASDAQ-listed biotechnology company focused on imetelstat, a telomerase inhibitor for blood cancers. In FY2025, the company generated $183.9 million in revenue. Geron develops its therapy within the healthcare sector around a single oncology asset designed to target malignant cell biology.
Today's Snapshot
GERN closed 4.6% below yesterday's close, while its sector was flat. The day ended with GERN within 3.6% of its 52-week low of 0.84.
Trading Volume
Above 10d avg 13.3M
13.7M
vs S&P 500 Today
Underperforming Market
-1.14%
Updated: November 20, 2026 at 21:12 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$0.96 - $1.31Sell
- RSI (14)35.43Neutral
- Stochastic %K (14, 3, 3)24.87Neutral
- MACD Level (12, 26)-0.06Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.